Consensus Neurogene Inc.

Equities

NGNE

US64135M1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-05-14 pm EDT			5-day change	1st Jan Change
31.27 ^USD	-4.14%		+0.03%	+51.80%

May. 08	Neurogene Insider Sold Shares Worth $300,043, According to a Recent SEC Filing	MT
May. 06	Neurogene announces inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE

Evolution of the Average Target: Neurogene Inc.

Evolution of the Target Price: Neurogene Inc.

Changes in Analyst Recommendations: Neurogene Inc.

20db507c1d1cd3c5c08d49.dSfFn9-G5HZZfTBYbrKgD-gFQVHJs8tg6EfXjo-DtEA.JFSz1IrVrh0JBGgyWoTTeJ5XIhCl3JMxizeV4ePIxRZNa7X8nvWcJgE4BA~e3248ae36ca43679034f22594eb9c3a1

Analysts' recommendations: Neurogene Inc.

Apr. 28	Guggenheim Initiates Neurogene at Buy With $69 Price Target	MT
Nov. 13	Gene therapy developer Neurogene's Q3 net loss widens	RE
25-10-09	Neurogene Plans to Initiate Dosing in Registrational Trial in Q4 2025	MT
25-05-16	Neurogene Shares Drop After Downgrade From Baird	MT
25-05-16	Baird Downgrades Neurogene to Neutral From Outperform, Adjusts Price Target to $24 From $38	MT
24-06-27	BMO Initiates Neurogene at Outperform With $65 Price Target	MT
24-06-11	Baird Initiates Neurogene With Outperform Rating, $54 Price Target	MT
24-04-29	Leerink Partners Starts Neurogene With Outperform Rating, $46 Price Target	MT
24-03-21	William Blair Initiates Neurogene With Outperform Rating	MT
24-01-08	HC Wainwright Starts Neurogene With Buy Rating, $45 Price Target	MT
24-01-05	Stifel Starts Coverage on Neurogene with Buy Rating, $31 Price Target	MT
23-05-09	Mizuho Adjusts Price Target on Neoleukin Therapeutics to $1.50 From $2, Keeps Neutral Rating	MT
23-01-03	Guggenheim Downgrades Neoleukin Therapeutics to Neutral From Buy	MT
22-11-15	Mizuho Downgrades Neoleukin Therapeutics to Neutral From Buy, Adjusts Price Target to $2 From $21	MT
22-11-15	Canaccord Genuity Downgrades Neoleukin Therapeutics to Hold From Buy, Adjusts Price Target to $1 From $10	MT
22-09-12	BofA Securities Downgrades Neoleukin Therapeutics to Underperform From Buy, Adjusts Price Target to $1 From $3	MT
22-09-12	HC Wainwright Adjusts Neoleukin Therapeutics' Price Target to $6 from $22, Maintains Buy Rating	MT
22-08-10	Stifel Nicolaus Adjusts Price Target for Neoleukin Therapeutics to $14 From $18, Maintains Buy Rating	MT
22-07-06	Canaccord Genuity Assumes Neoleukin Therapeutics at Buy with $10 Price Target	MT
22-05-31	Piper Sandler Adjusts Price Target on Neoleukin Therapeutics to $6 From $25, Reiterates Overweight Rating	MT
22-05-10	Guggenheim Adjusts Price Target for Neoleukin Therapeutics to $12 From $16, Maintains Buy Rating	MT
22-03-02	Piper Sandler Adjusts Neoleukin Therapeutics Price Target to $25 From $30, Maintains Overweight Rating	MT
21-08-06	NEOLEUKIN THERAPEUTICS : Piper Sandler Starts Neoleukin Therapeutics at Overweight with $30 Price Target	MT
21-01-06	NEOLEUKIN THERAPEUTICS : Stifel Starts Neoleukin Therapeutics at Buy With $18 Price Target	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	NEUROGENE INC.					+134.3%
	LONZA GROUP AG					+41.14%
	BEONE MEDICINES AG					+29.92%
	REVOLUTION MEDICINES, INC.					+20.92%
	IQVIA HOLDINGS INC.					+32.61%
	CELLTRION, INC.					+37.97%
	IONIS PHARMACEUTICALS, INC.					+29.82%
	EUROFINS SCIENTIFIC SE					+20.27%
	Average					+43.37%
	Weighted average by Cap.					+32.11%